source
- Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialCapricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In aEndpoints · 1h ago↗ source
- Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapyCompass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…